Karyopharm Therapeutics Inc.

KPTI | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.83

-$0.03 (-1.61%)

Sep 22, 2026, 2:33 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.61%

(1D)

Rating

Updated: Sep 12, 2026

34.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $41.59M

1D Range

1.83 1.92

52W Range

1.24 10.99

Valuation (TTM)

PE -0.14

PB -0.13

EV/EBITDA -1.72

Valuation (NTM)

Forward PE N/A

Forward PEG 0.00

Price Target $9.50

Cash Flow

FCF Yield -155.0%

SBC Adj. FCF Yield -182.6%

SBC Impact -17.8%

Margins

Gross Margin 95.9%

Operating Margin -56.2%

FCF Margin -44.6%

Growth (CAGR)

Revenue 3Y | 5Y 0.1% | 7.5%

Dil EPS 3Y | 5Y 18.2% | -21.8%

FCF 3Y | 5Y 32.7% | 5.3%

Returns

ROA -201.9%

ROE 77.6%

ROIC 376.9%

Financial Health

Net Debt

$144.53M

Current Ratio 0.79

Interest Coverage -1.67

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pat...

Sector Healthcare

Industry Biotechnology

Employees 228

IPO Date Nov 5, 2013

Website www.karyopharm.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 2, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$9.50

Upside

+419.13%

Buy (3)

Hold (1)

Sell (0)

Analyst Details ➞